237 related articles for article (PubMed ID: 24004830)
1. Comprehensive 3D-QSAR and binding mode of BACE-1 inhibitors using R-group search and molecular docking.
Huang D; Liu Y; Shi B; Li Y; Wang G; Liang G
J Mol Graph Model; 2013 Sep; 45():65-83. PubMed ID: 24004830
[TBL] [Abstract][Full Text] [Related]
2. Study on the active mechanism of β-secretase inhibitors by molecular simulations.
Tian YL; Lv M; Li JJ; Xu T; Zhai HL; Zhang XY
Eur J Pharm Sci; 2015 Aug; 76():138-48. PubMed ID: 25965961
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors.
Razzaghi-Asl N; Firuzi O; Hemmateenejad B; Javidnia K; Edraki N; Miri R
Bioorg Med Chem; 2013 Nov; 21(22):6893-909. PubMed ID: 24113238
[TBL] [Abstract][Full Text] [Related]
4. A method for induced-fit docking, scoring, and ranking of flexible ligands. Application to peptidic and pseudopeptidic beta-secretase (BACE 1) inhibitors.
Moitessier N; Therrien E; Hanessian S
J Med Chem; 2006 Oct; 49(20):5885-94. PubMed ID: 17004704
[TBL] [Abstract][Full Text] [Related]
5. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features.
Shimmyo Y; Kihara T; Akaike A; Niidome T; Sugimoto H
Biochim Biophys Acta; 2008 May; 1780(5):819-25. PubMed ID: 18295609
[TBL] [Abstract][Full Text] [Related]
6. A PM7 dynamic residue-ligand interactions energy landscape of the BACE1 inhibitory pathway by hydroxyethylamine compounds. Part I: The flap closure process.
Gueto-Tettay C; Martinez-Consuegra A; Zuchniarz J; Gueto-Tettay LR; Drosos-Ramírez JC
J Mol Graph Model; 2017 Sep; 76():274-288. PubMed ID: 28746905
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking and 3D-QSAR studies on the binding mechanism of statine-based peptidomimetics with beta-secretase.
Zuo Z; Luo X; Zhu W; Shen J; Shen X; Jiang H; Chen K
Bioorg Med Chem; 2005 Mar; 13(6):2121-31. PubMed ID: 15727865
[TBL] [Abstract][Full Text] [Related]
8. Molecular Docking and 3D Qsar Studies of C000000956 as a Potent Inhibitor of Bace-1.
Joseph OA; Babatomiwa K; Niyi A; Olaposi O; Olumide I
Drug Res (Stuttg); 2019 Aug; 69(8):451-457. PubMed ID: 30780168
[TBL] [Abstract][Full Text] [Related]
9. Chemometric design to explore pharmacophore features of BACE inhibitors for controlling Alzheimer's disease.
Hossain T; Mukherjee A; Saha A
Mol Biosyst; 2015 Feb; 11(2):549-57. PubMed ID: 25435329
[TBL] [Abstract][Full Text] [Related]
10. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
Kumar A; Srivastava G; Negi AS; Sharma A
J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of 1,4-dihydropyridine derivatives as BACE-1 inhibitors.
Choi SJ; Cho JH; Im I; Lee SD; Jang JY; Oh YM; Jung YK; Jeon ES; Kim YC
Eur J Med Chem; 2010 Jun; 45(6):2578-90. PubMed ID: 20303626
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region.
Probst GD; Bowers S; Sealy JM; Stupi B; Dressen D; Jagodzinska BM; Aquino J; Gailunas A; Truong AP; Tso L; Xu YZ; Hom RK; John V; Tung JS; Pleiss MA; Tucker JA; Konradi AW; Sham HL; Jagodzinski J; Toth G; Brecht E; Yao N; Pan H; Lin M; Artis DR; Ruslim L; Bova MP; Sinha S; Yednock TA; Gauby S; Zmolek W; Quinn KP; Sauer JM
Bioorg Med Chem Lett; 2010 Oct; 20(20):6034-9. PubMed ID: 20822903
[TBL] [Abstract][Full Text] [Related]
13. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors.
Iserloh U; Wu Y; Cumming JN; Pan J; Wang LY; Stamford AW; Kennedy ME; Kuvelkar R; Chen X; Parker EM; Strickland C; Voigt J
Bioorg Med Chem Lett; 2008 Jan; 18(1):414-7. PubMed ID: 18023580
[TBL] [Abstract][Full Text] [Related]
14. Ensemble-docking approach on BACE-1: pharmacophore perception and guidelines for drug design.
Limongelli V; Marinelli L; Cosconati S; Braun HA; Schmidt B; Novellino E
ChemMedChem; 2007 May; 2(5):667-78. PubMed ID: 17407105
[TBL] [Abstract][Full Text] [Related]
15. High throughput virtual screening and E-pharmacophore filtering in the discovery of new BACE-1 inhibitors.
Muthusamy K; Singh KhD; Chinnasamy S; Nagamani S; Krishnasamy G; Thiyagarajan C; Premkumar P; Anusuyadevi M
Interdiscip Sci; 2013 Jun; 5(2):119-26. PubMed ID: 23740393
[TBL] [Abstract][Full Text] [Related]
16. Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase.
Sauder JM; Arthur JW; Dunbrack RL
J Mol Biol; 2000 Jul; 300(2):241-8. PubMed ID: 10873463
[TBL] [Abstract][Full Text] [Related]
17. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies.
John S; Thangapandian S; Sakkiah S; Lee KW
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S28. PubMed ID: 21342558
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of 2,3,5-substituted imidazolidin-4-one inhibitors of BACE-1.
Barrow JC; Rittle KE; Ngo PL; Selnick HG; Graham SL; Pitzenberger SM; McGaughey GB; Colussi D; Lai MT; Huang Q; Tugusheva K; Espeseth AS; Simon AJ; Munshi SK; Vacca JP
ChemMedChem; 2007 Jul; 2(7):995-9. PubMed ID: 17458843
[No Abstract] [Full Text] [Related]
19. In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease.
Semighini EP
Chem Biol Drug Des; 2015 Sep; 86(3):284-90. PubMed ID: 25476252
[TBL] [Abstract][Full Text] [Related]
20. [Application of an R-group search strategy into three-dimensional quantitative structure-activity relationship of HEA beta-secretase inhibitors and molecular virtual screening].
Shi B; Liu Y; Li Y; Wang G; Liang G
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2014 Feb; 31(1):196-204. PubMed ID: 24804511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
